Last reviewed 2026-04-23 · How we verify

EU Simponi

Simponi is a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation in autoimmune diseases.

Simponi is a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation in autoimmune diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.

At a glance

Mechanism of action

Simponi (golimumab) is a fully human monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha, it suppresses the inflammatory cascade underlying autoimmune conditions. This mechanism reduces joint inflammation, systemic inflammation, and disease progression in conditions like rheumatoid arthritis and inflammatory bowel disease.

Approved indications

• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Ulcerative colitis
• Crohn's disease

Common side effects

• Injection site reactions
• Upper respiratory tract infections
• Nasopharyngitis
• Tuberculosis reactivation
• Serious infections

Key clinical trials

• A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants (PHASE1)
• Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX (PHASE3)
• Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects (PHASE1)
• Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis (PHASE3)
• A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi® (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.